Shuhaiber S, Pastuszak A, Schick B, Matsui D, Spivey G, Brochu J, Koren G
The Motherisk Program, Department of Pediatrics and Research Institute, The Hospital for Sick Children and the University of Toronto, Ontario, Canada.
Neurology. 1998 Aug;51(2):581-3. doi: 10.1212/wnl.51.2.581.
We prospectively compared pregnancy outcome after exposure to sumatriptan with that of disease-matched controls and nonteratogen controls. There were no differences in the rates of live births, spontaneous abortions, therapeutic abortions, or major birth defects among the three groups. This first prospective report suggests that the use of sumatriptan during organogenesis is not associated with an apparent increased risk of major birth defects.
